Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma: a Single-center, Prospective, Phase II Umbrella Clinical Study

NCT06211790 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06211790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06211790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma: a Single-center, Prospective, Phase II Umbrella Clinical Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
January 16, 2024
Completion date
December 30, 2026
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, renal cell carcinoma, renal clear cell carcinoma